1. Market Research
  2. > Healthcare
  3. > Health Facility Market Trends
  4. > Kindred Healthcare, Inc. - Strategy and SWOT Report

Kindred Healthcare, Inc. - Strategy and SWOT Report

  • January 2016
  • -
  • MarketLine
  • -
  • 29 pages

Introduction

Kindred Healthcare, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Kindred Healthcare, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Kindred Healthcare, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Kindred Healthcare, Inc. including a breakdown and examination of key business segments

- Intelligence on Kindred Healthcare, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Kindred Healthcare, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Kindred Healthcare (Kindred or 'the company'), through its subsidiaries, operates hospitals, nursing centers and rehabilitation centers in the US. The company is headquartered in Louisville, Kentucky. It employed about 61,500 people, of which 38,700 were full-time and 22,800 were part-time and per diem employees, as on December 31, 2014. The company recorded revenues of $5,027.6 million during the financial year ended December 2014 (FY2014), an increase of 5.3% over FY2013. The operating profit of the company was $169.3 million in FY2014, as compared to an operating profit of $52 million in FY2013. The net loss of the company was $79.8 million in FY2014, as compared to a net loss of $168.5 million in FY2013.

Reasons to Purchase:

- Gain understanding of Kindred Healthcare, Inc. and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Kindred Healthcare, Inc. as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Kindred Healthcare, Inc.’s business structure, strategy and prospects

Table Of Contents

Kindred Healthcare, Inc. - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NT-3 ...

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global ...

Hospital for Special Surgery - Product Pipeline Analysis, 2016 Update

Hospital for Special Surgery - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • December 2016
  • by GlobalData

Summary Hospital for Special Surgery (HSS) is a healthcare service provider that provides surgery services in the areas of orthopedics, rehabilitation and rheumatology. The hospital discovers and develops ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.